Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand 123I-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.

Original publication




Journal article


Neurochem Res

Publication Date





643 - 651


Aged, Aged, 80 and over, Alzheimer Disease, Azetidines, Brain, Cholinesterase Inhibitors, Donepezil, Female, Humans, Image Processing, Computer-Assisted, Indans, Male, Neuropsychological Tests, Nootropic Agents, Observer Variation, Pilot Projects, Piperidines, Pyridines, Radiopharmaceuticals, Receptors, Nicotinic, Tomography, Emission-Computed, Single-Photon